NSGO-FANDANGO/ENGOT-EN1 : a randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/ recurrent endometrial cancer
Source
Gynecologic oncology - ISSN 0090-8258-199 (2025) p. 79-87
Is switching to T-DM1 still justified in HER2-negative residual breast cancer after neoadjuvant systemic therapy?
Source
The Breast - ISSN 0960-9776-81 (2025) p. 1-2
Exploring immunological dynamics in breast cancer during systemic therapy
Source
Antwerp, University of Antwerp, Faculty of Medicine and Health Sciences, 2025,155 p.
Dynamics of SERPINA3 in response to anthracycline treatment and cardiovascular dysfunction
Source
Cardio-Oncology - ISSN 2057-3804-11:1 (2025) p. 1-13
Tumor microenvironment modulation by tumor-associated macrophages : implications for neoadjuvant chemotherapy response in breast cancer
Source
Breast cancer : targets and therapy - ISSN 1179-1314-17 (2025) p. 211-224